Alirocumab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Alirocumab ?
Monoclonal antibody
Source Human
Target neural apoptosis-regulated proteinase 1
Clinical data
Legal status
?
Identifiers
CAS number 1245916-14-6
ATC code None
Chemical data
Formula C6472H9996N1736O2032S42 
Mol. mass 146.0 kDa

Alirocumab is a human monoclonal antibody designed for the treatment of hypercholesterolemia.[1] This therapeutic is also known by the codes REGN727 and SAR236553.[2]

This drug was discovered by Regeneron Pharmaceuticals and is being co-developed by Regeneron and Sanofi.

References[edit]

  1. ^ International Nonproprietary Names for Pharmaceutical Substances (INN), World Health Organization
  2. ^ Sheridan, C (2013). "Phase 3 data for PCSK9 inhibitor wows". Nature Biotechnology 31 (12): 1057–8. doi:10.1038/nbt1213-1057. PMID 24316621.  edit